Highly active antiretroviral therapy
Researchers at the University of Kinshasa have conducted a study to describe the lipid profile of people living with HIV (PLHIV) on antiretroviral therapy in a hospital setting in Kinshasa, the Democratic Republic of the Congo. The study, published in the Orapuh Journal, found that despite the beneficial effects of
HIV
A recent study published in the Lancet HIV has shed light on the effectiveness of pre-exposure prophylaxis (PrEP) medications in preventing new HIV infections. The research, conducted by a team of scientists at Emory University, analyzed data from a nationwide commercial pharmacy database and public health surveillance data to assess
Drug approval
The United States Food and Drug Administration has approved Lenacapavir (LEN), a highly effective HIV prevention medicine that can reduce the risk of transmission by 99.9 per cent. This approval has significant implications for global efforts to combat the spread of HIV, particularly in India, where Dr. I.S.
HIV
A groundbreaking drug, Lenacapavir, is poised to make a significant impact in the fight against HIV, with the potential to "end the pandemic" according to UNAids executive director Dr. Winnie Byanyima. The twice-yearly injection has shown remarkable results in clinical trials, preventing HIV infection in individuals. As regulatory
AIDS (Disease)
Cambodia has made significant strides in its efforts to combat HIV and AIDS, according to a recent meeting between high-ranking government officials and Winnie Byanyima, Executive Director of UNAIDS. The country has achieved remarkable success, including a decline in HIV prevalence from 3% in 1996 to just 0.5% in
Epidemics
Five years into the US national Ending the HIV Epidemic (EHE) plan, it is a critical time to examine what has been learned and what still needs to be studied to achieve its 2030 goals of reducing new HIV infections by 90%. The EHE plan has made significant progress, with
HIV
Researchers have established a network to study real-world implementation of evidence-based HIV interventions across US contexts, with a focus on generating knowledge around implementation strategies to support the achievement of Ending the HIV Epidemic goals. The Network for Implementation Science in HIV (NISH) represents diverse priority jurisdictions and includes participation
Diseases
In Zimbabwe and sub-Saharan Africa, a new and deadly threat is emerging in the shadow of the HIV epidemic: Advanced HIV Disease (AHD). Despite remarkable progress in the fight against HIV, thousands of lives are still being lost to AHD, a condition linked to late presentation, untreated HIV, or returning
AIDS treatment
As Gilead Sciences expands lenacapavir, a long-acting HIV treatment, to 120 countries through voluntary licensing agreements with six generic manufacturers, the AIDS Healthcare Foundation (AHF) is highlighting the alarming exclusions of key HIV-affected countries in Latin America and others from the deal. According to AHF, this license excludes 2 million
HIV
WHO recently welcomed the findings of the PURPOSE-2 trial, an interim analysis of which demonstrated a remarkable 96% reduction in the risk of acquiring HIV among participants who received long-acting injectable lenacapavir (LEN). This HIV-1 capsid inhibitor, administered subcutaneously twice a year, was found to be highly effective in preventing
HIV
Researchers from Wright State University have conducted a comprehensive study to examine the effects of internalized HIV stigma on viral non-suppression among patients in HIV care in the US. The longitudinal observational clinical cohort sample included 9,574 individuals, with 81.1% being male and 41.4% being Black, non-Hispanic.
HIV
New research on Immune System Diseases and Conditions - HIV/AIDS has found a high prevalence of paid sex among HIV positive individuals in Kinshasa, Democratic Republic of the Congo. According to the study published in the Archives of Sexual Behavior, paid sex is associated with other sexual and consumption
